Search

Displaying results 5061 - 5070 of 10000 in total
  1. Drug

    Esuberaprost

    go.drugbank.com/drugs/DB18464
    Investigational

    Esuberaprost (GP-1681), a drug intended for participants with pulmonary arterial hypertension, was under investigation in clinical trial NCT03657095 to evaluate its efficacy and safety.

  2. Drug

    Vibecotamab

    go.drugbank.com/drugs/DB18872
    Investigational

    Vibecotamab is under investigation in clinical trial NCT05285813 (A Phase II Study of Vibecotamab (Xmab14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure).

  3. Drug

    Anti-CD19 CAR-T cells

    go.drugbank.com/drugs/DB21913
    Investigational

    CD19 CAR-T is under investigation in clinical trial NCT05618041 (The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients with Hematological Malignancies).

  4. Drug

    Zamubafusp alfa

    go.drugbank.com/drugs/DB32269
    Investigational

    [L55038] It consists of a humanized IgG1 and p5R which is a pan-amyloid reactive peptide.[L55038]

  5. Drug

    UDP-alpha-D-xylose

    go.drugbank.com/drugs/DB01713
    Experimental

    The decarboxylation product of UDPglucuronic acid, which is used for formation of the xylosides of seryl hydroxyl groups in mucoprotein synthesis. Also forms plant xylans.

  6. Drug

    Clevudine

    go.drugbank.com/drugs/DB06683
    Investigational

    Synonyms: L-FMAU, 2'-Fluoro-5-methyl-beta-L-arabinofuranosyluracilCategories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Pinatuzumab vedotin

    go.drugbank.com/drugs/DB15432
    Investigational

    Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or … Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).

  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]

  9. Drug

    Amperozide

    go.drugbank.com/drugs/DB08927
    Experimental

    Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication … Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons.

  10. Drug

    Dendritic cells vaccine

    go.drugbank.com/drugs/DB15803
    Investigational

    The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.